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Abstract
HER2 (ERBB2) gene status serves as a strong predictive marker of response to HER2-targeted agents in invasive breast
cancers, albeit with heterogeneous response. Our aim was to determine the distribution and prognosis of HER2 groups by
ﬂuorescent in situ hybridization (FISH) using the updated 2018 American Society of Clinical Oncology–College of
American Pathologist (ASCO–CAP) guidelines. We identiﬁed 226 cases of equivocal or positive HER2 FISH invasive
breast cancer (interpreted by ASCO–CAP guidelines at the time of reporting) who received HER2-targeted agents from 2006
to 2017. We subcategorized Group 1 further into three subgroups: low ampliﬁed (HER2/CEP17 ratio ≥ 2.0–2.99, mean
HER2/cell 4.0–5.9), ampliﬁed (HER2/CEP17 ratio ≥ 2.0–2.99, mean HER2/cell ≥ 6), and excessive ampliﬁcation (HER2/
CEP17 ratio ≥ 3.0, mean HER2/cell ≥ 4.0). Outcomes studied were recurrence, metastasis, second breast primary, diseasespeciﬁc survival (DSS), and overall survival (OS). Univariate analysis showed that the ﬁve categories of HER2 FISH were
signiﬁcantly associated with OS (p < 0.01), speciﬁcally higher HER2 ampliﬁcation was associated with fewer deaths. HER2
FISH status also statistically signiﬁcantly relates to DFS (p < 0.01) and metastasis (p = 0.01) but not with recurrence or
second breast primary in our study. Tumor type and HER2 ISH Groups are independent predictors for both OS and DFS in
our cohort. The proposed Group 1 subcategories were signiﬁcantly associated with OS (p < 0.01) and DFS (p < 0.01),
excessive HER2 ampliﬁcation was associated with longer median survival. The Cox regression models showed better
survival outcomes for the excessive ampliﬁcation subgroup than the low ampliﬁed subgroup, with OS (hazard ratio = 0.63,
95% CI 0.42–0.93) and DFS (HR = 0.55, 95% CI 0.37–0.83). We demonstrated that in HER2 FISH Group 1 patients, high
HER2 ampliﬁcation was signiﬁcantly associated with longer OS and DFS; these patients seem to beneﬁt more from HER2targeted regimens. We recommend reporting these Group 1 subcategories when assessing HER2 FISH.

Introduction

This study was presented at the United States and Canadian Academy
of Pathology (USCAP) 109th Annual Meeting, Los Angeles, CA,
February 29 to March 5, 2020.
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Approximately 15–20% of invasive breast cancers show
overexpression of human epidermal growth factor receptor
type 2 (HER2) protein, a form of a transmembrane tyrosine
kinase receptor, which is encoded by the ERBB2 gene,
located on chromosome 17 (17q12) [1, 2]. Prior to the use
of HER2-targeted agents, these aggressive cancers were
associated with adverse outcomes. The use of HER2targeted therapy such as trastuzumab (Herceptin), lapatinib
(Tykerb/Tyverb), pertuzumab (Perjeta), and adotrastuzumab emtansine/T-DM1 (Kadcyla) has signiﬁcantly
improved survival and revolutionized the treatment of
HER2-positive breast cancers [3–5]. However, these medications are costly and associated with devastating side
effects like cardiotoxicity. Therefore, accurate assessment
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of HER2 status plays a pivotal role in the management of
breast cancer in these patients. As a result, the American
Society of Clinical Oncology (ASCO) and the College of
American Pathologists (CAP) produced algorithm using
immunohistochemistry (IHC) testing and in situ hybridization (ISH) pertaining to standardization and interpretation of
HER2 diagnostic tests.
Since its introduction in 2007 [6], the ASCO–CAP
guidelines have been updated twice, in 2013 [7] and 2018
[8]. The latest ASCO–CAP guidelines introduced ﬁve ISH
categories, incorporated IHC testing with ISH in the analysis of a subset of cases, and eliminated the equivocal
category. The equivocal category had existed in the preceding two guideline versions and had posed a challenge to
many treating oncologists because they lacked clear
guidelines on when and how to use HER2-targeted agents.
ASCO–CAP 2018 guidelines [8] introduced ﬁve groups
based on HER2 testing using validated dual-probe ISH
assay. The “classical groups” (Groups 1 and 5), i.e., when
both the HER2/chromosome enumeration probe 17
(CEP17) ratio and the number of HER2 signals per cell are
simultaneously ampliﬁed or not, had the same threshold as
described in the 2013 updates. However, the “nonclassical
groups” (Groups 2–4), when the ratio and the number of
HER2 signals per cell results are discordant with only one
being “ampliﬁed,” had signiﬁcant changes in this latest
2018 update. This yielded the following categories: Group 1
(HER2/chromosome enumeration probe 17 [CEP17] ratio ≥
2 + HER2 signal ≥ 4 per cell), Group 2 (HER2/CEP17 ratio
≥ 2 + HER2 signal < 4 per cell), Group 3 (HER2/CEP17
ratio <2 + HER2 signal ≥ 6 per cell), Group 4 (HER2/
CEP17 ratio < 2 + HER2 signal ≥ 4–<6 per cell), and Group
5 (HER2/CEP17 ratio < 2 + HER2 signal < 4 per cell).
Additional work is required if a nonclassical group (Groups
2–4) is encountered; a ﬁnal result is reached by combining
the IHC with the ISH result, and if the IHC is 2+, then ISH
should be reassessed by an additional observer, who has
been blinded to previous ISH results, counting at least 20
cells that include the area of invasive cancer with IHC 2+
staining.
The aim of our study is to investigate the impact on
invasive breast cancer patients of the categories deﬁned by
the 2018 ASCO–CAP guidelines on HER2 classiﬁcation
who received HER2-targeted agents. Also, to describe the
histopathologic features and prognosis of HER2 ISH
Groups.

Material and methods
Following institutional review board approval from the
Henry Ford Health System, we retrospectively retrieved all
cases of breast cancer from 2006 to 2017, either primary or

metastatic, in which the ﬂuorescent in situ hybridization
(FISH) was either positive or equivocal at the time of
reporting and the patient subsequently received HER2targeted agents. Breast cancer patients who had not received
HER2-targeted agents were excluded from the study
regardless of the FISH results. In addition, cases in which
FISH was not performed were excluded.
Histopathology features and other results were directly
extracted from our institutional pathology reports, and the
clinical information, including outcomes, was retrieved
from the patients’ electronic medical records. The recorded
variables include the following: age, race, type of surgery,
type of HER2-targeted therapy, and its complications and
whether neoadjuvant, adjuvant, radiotherapy, or hormonal
therapy was given. The following pathologic features were
recorded: tumor type (ductal carcinoma of no special type
[NST], lobular carcinoma, special ductal type carcinoma, or
mixed ductal and lobular carcinoma), Nottingham grade,
focality (unifocal or multifocal), presence of ductal carcinoma in situ (DCIS), presence of lobular carcinoma in situ,
status of ﬁnal margins for both invasive and DCIS, presence
of lymphovascular invasion, treatment effect—if neoadjuvant therapy was given (pathological complete response
[pCR], probable or no response) as described in the
American Joint Committee on breast cancer staging at the
time of reporting [9, 10], tumor stage (pT), lymph node
stage (pN), number of positive sentinel lymph nodes, status,
and percentage, of both estrogen receptors (ER) and progesterone receptors (PR) by following CAP cancer protocol
guidelines and Allred scoring system [11], proliferation
index by MIB1 IHC documented in the pathologic report as
percentage of strongly positive tumor nuclei of invasive
component [11], HER2 IHC (0–3+), and ﬁnally HER2
FISH ratio with the average HER2 signals per cell using the
dual-probe FISH assay. The outcomes recorded in our study
include development of metastasis, second primary breast
cancer, recurrence, disease-free survival (DFS), and overall
survival (OS).
The above variables were assessed by three of the
authors (MA, BA, and HM). The ﬁnal cohort included a
total of 226 patients with breast cancer in which HER2
FISH was performed and HER2-targeted therapy was given.

HER2 immunohistochemistry (IHC)
ER (Clone EP1from Dako, Agilent Technologies, Inc.,
Santa Clara, CA, USA) and PR (Clone PgR 636 from Dako)
stains were performed as standard of practice for all the
invasive breast cancers and scored following Allred scoring
system [11]. HER2 IHC (HercepTest from Dako) was
performed at the time of routine specimen processing and
CAP guidelines were followed especially those pertaining
to specimen handling, ﬁxation, cold ischemia time, and
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interpretation of IHC tests [11]. Results were signed out by
experienced breast pathologists.

HER2 ﬂuorescence in situ hybridization (FISH)
Prior to routine sign out, ISH analysis for HER2 protein was
performed using the dual-probe HER2/CEP17 FISH assay
using Vysis dual FISH probe (FDA Approved PathVysion
HER2 DNA Probe Kit from Abbott Molecular, Inc., Abbott
Park, Illinois, USA).
HER2 FISH was performed on 226 specimens and HER2
FISH ratio with the average HER2 signals per cell were
recorded for all cases. The test was interpreted using the
ASCO–CAP guidelines at the time of reporting and then
reclassiﬁed using the latest 2018 ASCO–CAP guidelines
into ﬁve groups and by incorporating HER2 IHC, when
applicable. FISH results were reviewed by three of the
authors (MA, JS, and DC).

Statistical analysis
To assess signiﬁcance of associations between different
variables, we used Mann–Whitney U, chi-square, and Fisher’s
exact tests. For clinical outcomes, Kaplan–Meier curves were
generated and compared using log rank tests. We performed
multivariate analysis and additional univariate analysis using
Cox proportional hazards models. A p value of <0.05 was
considered statistically signiﬁcant in our study. All tests were
performed (by two authors) using R software (version 3.6.2,
R Foundation for Statistical Computing, Vienna, Austria).

Results
Over this time period, our laboratory performed a total of
729 FISH tests, out of which 274 patients were either
positive or equivocal at the time of reporting. Out of these
274 cases, 226 patients were treated with HER2-targeted
agents. The median age of our cohort is 65 years (range
26–98); the racial distribution in our cohort was 58%
Caucasians, 24% African Americans, 1.5% other races, and
16.5% unknown. The median HER2 FISH ratio was 2.47
(range 1.18–21) and HER2 signal/cell was 6.30 (range
2.09–21). Surgical intervention in the form of mastectomy,
lumpectomy, or excision was recorded in 198 (88%)
patients. A total of 70 (31%) patients received neoadjuvant
chemotherapy, 153 (68%) hormonal therapy, 188 (83%)
adjuvant chemotherapy, and 146 (65%) radiotherapy.
Almost all patients received trastuzumab (Herceptin),
either alone in 145 (64%) patients or in combination with
pertuzumab (Perjeta) in 72 (32%) patients or lapatinib
(Tykerb/Tyverb) in 2 (1%) patients. The combination of
lapatinib (Tykerb/Tyverb) with trastuzumab (Herceptin)

was part of a clinical trial while the combination of pertuzumab (Perjeta) with trastuzumab (Herceptin) was part of
standard of care for high-risk patients and noted more frequently in the neoadjuvant setting. The use of trastuzumab
(Herceptin) alone was signiﬁcantly associated with longer
median OS (281.4 weeks, p < 0.01) and DFS (262.9 weeks,
p < 0.01). Controlling for tumor type and 2018 ASCO–CAP
ISH Groups (the two independent predicators for OS and
DFS in our cohort) showed that the use of trastuzumab
(Herceptin) with pertuzumab (Perjeta) or lapatinib (Tykerb/
Tyverb) was independently associated with higher hazard
ratio (HR) of death than trastuzumab (Herceptin) alone
for OS (HR = 1.98, 95% CI 1.41–2.76; p < 0.01) and DFS
(HR = 2.17, 95% CI 1.50–3.12; p < 0.01).
HER2-targeted medication side effects were reported in
27 (12%) patients, 23/226 (10% of the patients) suffered
cardiac side effects. The median follow-up was 214.8 weeks
(range 4.7–873.1).
Breast cancer cases were 88% ductal (NST), 5% special
ductal, 4% lobular, 2% invasive mammary (not speciﬁed),
and 1% mixed ductal and lobular. The Nottingham grade
was 1/well-differentiated in 8 cases, 2/moderately differentiated in 90 cases, 3/poorly differentiated in 115 cases and
it was not recorded in 13 cases. The tumor was unifocal in
47 cases while it was multifocal in 23 cases and was not
recorded in 156 cases. DCIS was present in 111 cases while
lobular carcinoma in situ was found in 7 cases. Only six
cases had positive margins for invasive carcinoma and three
cases had positive margins for DCIS. Lymphovascular
invasion was seen in 56 cases. For patients who received
neoadjuvant therapy, 9 patients had complete response with
no residual cancer while 61 patients had either probable or
no response. The tumors were staged as follows: ypT0 13
cases (6%), ypTis 1 case (0.5%), pT1 104 cases (46%)
[1mic:1 case, 1a:6 cases, 1b:33 cases, and 1c:64 cases], pT2
56 cases (24%), pT3 8 cases (3.5%), pT4 6 cases (3%), and
38 (17%) unknown cases. Nodal staging was pN0 in 116
cases (52%), micrometastasis in 5 cases (2%), pN1 in 32
cases (14%), pN2 in 20 cases (9%), pN3 in 5 cases (2%),
and in 48 (21%) the node status was unknown. The number
of positive sentinel lymph nodes was 0 in 101 (45%) cases,
1 in 18 (8%) cases (including 1 with individual tumor cells
and 1 micrometastasis), more than 1 in 11 (5%) cases, and
the pN was unknown in 96 (42%) cases. ER was positive in
160 (71%) cases, while PR was positive in 132 (58%) cases.
The median MIB1 was 27% (range 2–95). HER2 IHC was
negative (0–1+) in 7 (3%) cases, equivocal (2+) in 192
(85%) cases, and positive (3+) in 25 (11%) cases.
Overall, 164 (73%) patients were alive without disease,
17 (7%) alive with disease, 34 (15%) died of breast cancer,
and 11 (5%) died due to other causes. Forty-ﬁve (20%)
patients developed metastasis, ten (4%) patients had local
recurrence, and six (3%) patients had second breast primary.
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Fig. 1 Class migration of cases
among different ASCO–CAP
HER2 guidelines. ASCO–CAP
American Society of Clinical
Oncology–College of American
Pathologist, ISH in situ
hybridization.

Impact of ASCO–CAP ISH guidelines change
Figure 1 shows our cohort (patients who received HER2targeted agents from 2006 to 2017) case distribution when
2007, 2013, and 2018 ASCO–CAP ISH guidelines are applied.
When applying 2007 ASCO–CAP ISH guidelines
(ampliﬁed when ratio of HER2 to CEP17 > 2.2 or average
HER2 gene copy-number > 6 signals/nucleus, equivocal
when HER2/CEP17 ratio of 1.8–2.2 or average HER2 gene
copy-number 4–6 HER2 signals/nucleus, and negative
when HER2/CEP17 ratio of <1.8 or average HER2 gene
copy-number of <4 signals/nucleus) to our cohort, 174
cases would have been categorized as ISH-positive and 52
cases would have been categorized as equivocal. As
expected, no negative cases were encountered in our
exclusively HER2-treated cohort.
When 2013 ASCO–CAP ISH guidelines were applied
(ampliﬁed when dual-probe HER2/CEP17 ratio ≥ 2.0; with
an average HER2 copy-number ≥ 4.0 signals/cell or
<4.0 signals/cell, or dual-probe HER2/CEP17 ratio < 2.0;
with an average HER2 copy-number ≥6.0 signals/cell,
equivocal when dual-probe HER2/CEP17 ratio <2.0 with an
average HER2 copy-number ≥4.0 and <6.0 signals/cell, and
negative when dual-probe HER2/CEP17 ratio < 2.0 with an
average HER2 copy-number <4.0 signals/cell), 204 cases
would have been classiﬁed as ISH-positive, 19 equivocal
cases, and 3 negative cases. The 2007–2013 change of
guidelines resulted in 15% increase in positive cases (as
most of the 2007 equivocal cases reclassiﬁed as positive in
2013) and 63% decrease in equivocal cases was observed.
The reclassiﬁcation of cases according to 2018
ASCO–CAP ISH guidelines and after incorporating HER2
IHC results (in Groups 2–4) showed the following: 17 of 204
positive cases (2013 guidelines) were reclassiﬁed as negative
according to the 2018 guidelines. Of the 19 equivocal cases
from the 2013 guidelines, 1 case became positive (2018 criteria) while the rest of the cases were classiﬁed as negative.
The ﬁnal distribution of cases is as follows: 188 positive cases
(8% reduction from 2013 guidelines) and 38 negative cases
(92% increase in comparison to 2013 guidelines). The

equivocal category was eliminated from the 2018 guidelines.
Overall, 36 (15.9%) cases changed categories from the 2013
to the 2018 guidelines. Figure 1 summarizes the case
migration according to different ASCO–CAP guidelines.
Using log rank analysis, the 2018 ASCO–CAP reclassiﬁcation of cases was signiﬁcantly associated with OS
(p = 0.003) and DFS (p = 0.001). The 2013 ASCO–CAP
classiﬁcation was signiﬁcantly associated with OS (p =
0.02) but not with DFS (p = 0.07). Signiﬁcant statistical
association was observed in both OS (p < 0.01) and DFS
(p < 0.01) when 2007 ASCO–CAP guidelines were applied.

ASCO–CAP HER2 ISH Groups
Our cases were grouped using the 2018 ASCO–CAP newly
introduced ﬁve ISH Groups: Group 1/classical ampliﬁed
(HER2/CEP17 ratio ≥ 2 + HER2 signal ≥ 4 per cell), Group
2/“nonclassical” monosomy (HER2/CEP17 ratio ≥ 2 +
HER2 signal < 4 per cell), Group 3/“nonclassical” coampliﬁed/polysomy (HER2/CEP17 ratio < 2 + HER2 signal
≥ 6 per cell), Group 4/“nonclassical” previously called equivocal (HER2/CEP17 ratio < 2 + HER2 signal ≥ 4–<6 per
cell), and Group 5/classical non-ampliﬁed (HER2/CEP17
ratio < 2 + HER2 signal <4 per cell). HER2 IHC was referred
to when needed (Groups 2–4) and as instructed in the latest
guidelines to reach a ﬁnal result as to whether the HER2 FISH
is positive or negative. Figure 2 shows the distribution of our
cohort by 2018 ASCO–CAP categories and shows different
visual examples of HER2 FISH within each group. Table 1
shows the histopathologic features of breast cancer by HER2
FISH Group; no signiﬁcant relationship between the groups
and the variables was observed including HER2 IHC.
Univariate analysis using the log rank test showed that
the HER2 FISH Groups were signiﬁcantly associated with
OS (p < 0.01; Fig. 3), higher HER2 ampliﬁcation was
associated with fewer deaths, possibly reﬂecting a better
response to HER2-targeted therapy. HER2 FISH status also
statistically signiﬁcantly relates to DFS (p < 0.01; Fig. 4)
and metastasis (p = 0.01) but not with recurrence (p = 0.49)
or second primary (p = 0.37) in our cohort.
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Fig. 2 Case distribution among different ASCO–CAP Groups. ASCO–CAP American Society of Clinical Oncology–College of American
Pathologist, CEP chromosome enumeration probe, FISH ﬂuorescent in situ hybridization, HER2 human epidermal growth factor receptor 2.

The multivariate analysis showed that tumor type and
HER2 ISH Groups are independent predictors for both OS
and DFS in our HER2-treated cohort (Tables 2 and 3).

Group 1/classical ampliﬁed (HER2/CEP17 ratio ≥ 2 +
HER2 signal ≥ 4 per cell)
The vast majority of our cohort belonged to this group, 176
(78%) out of 226 cases. The median age was 65 years
(range 26–98), median HER2 FISH ratio was 2.795 (range

2–21), and median HER2 signal/cell was 6.99 (range
4.08–21). There were 159 (93%) cases of invasive ductal
carcinoma NST, 6 (4%) cases were special ductal type
carcinoma, 5 (3%) cases were lobular carcinoma, and 1
(1%) case was mixed carcinoma. Around 57% of Group 1
cases were poorly differentiated and 86% belonged to
pathologic stage pT1 and pT2. Group 1 patients were given
trastuzumab (Herceptin) alone in 114 (64%) patients, pertuzumab (Perjeta) and trastuzumab (Herceptin) in 57 (32%)
patients, lapatinib (Tykerb/Tyverb) and trastuzumab
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Table 1 Histopathologic
characteristics of cases within
each 2018 ASCO–CAP Groups.

Group 1

Group 2

Group 3

Group 4

Group 5

p value Total

Tumor type
Ductal NST

159 (90%) 14 (82%)

9 (82%) 15 (79%)

3 (100%) 0.09

200 (89%)

Lobular

5 (3%)

1 (6%)

1 (9%)

1 (5%)

0

8 (4%)

Special type

6 (6%)

1 (6%)

1 (9%)

3 (16%)

0

11 (5%)

Mixed

1 (1%)

1 (6%)

0

2 (1%)

Grade 1

6 (3%)

1 (6%)

Grade 2

65 (37%)

6 (35%)

Grade 3

93 (53%) 10 (59%)

0

0

Nottingham grade
0

1 (5%)

0

0.38

8 (4%)

7 (63%) 10 (53%)

2 (67%)

90 (40%)

3 (27%)

8 (42%)

1 (33%)

115 (51%)

1 (5%)

1 (33%) 0.69

Pathologic tumor stage (pT)
ypT0 and ypTis

12 (7%)

0

pT1

82 (47%) 10 (59%)

5 (45%)

7 (37%)

0

104 (46%)

pT2

42 (24%)

4 (24%)

4 (36%)

6 (32%)

0

56 (25%)

pT3

5 (3%)

1 (6%)

pT4

4 (2%)

0

0

0
1 (9%)

1 (5%)
1 (5%)

1 (33%)

14 (6%)

8 (4%)

0

6 (3%)

Pathologic lymph node stage (pN)
pN0
pNmic

93 (53%) 12 (71%)
2 (1%)

0

3 (27%)

8 (42%)

0

2 (18%)

1 (5%)

0

3 (16%)

pN1

25 (14%)

1 (6%)

1 (9%)

pN2

14 (8%)

2 (12%)

2 (18%)

pN3

4 (2%)

0

0

9/54 (17%) 0/3

0/4

0.30

116 (51%)
5 (2%)

2 (67%)

32 (14%)

2 (11%)

0

20 (9%)

1 (5%)

0

5 (2%)

Neoadjuvant therapy
Pathological complete
response (pCR)

0/8

0/1

0.11

9/70 (13%)

3 (100%) 0.51

160 (71%)

Estrogen receptor (ER)
ER+
ER−

124 (70%) 12 (71%)
48 (27%)

5 (29%)

9 (81%) 12 (63%)
1 (9%)

7 (37%)

0

61 (27%)

Progesterone receptor (PR)
PR+

97 (55%) 12 (71%)

9 (81%) 12 (63%)

2 (67%) 0.13

PR−

75 (43%)

5 (29%)

1 (9%)

1 (33%)

5 (3%)

2 (12%)

7 (37%)

132 (58%)
89 (39%)

HER2 IHC
0–1+
2+
3+

0

0

146 (83%) 15 (88%) 10 (91%) 18 (95%)
23 (13%)

0

1 (9%)

1 (5%)

0
3 (100%)
0

0.29

7 (3%)
192 (85%)
25 (11%)

ASCO–CAP American Society of Clinical Oncology–College of American Pathologist, ductal NST ductal
carcinoma of no special type, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry.

(Herceptin) in 2 (1%) patients, and lapatinib (Tykerb/
Tyverb) alone in 1 (0.5%) patient. Of note, 9 of 54 (17%)
cases in Group 1 received neoadjuvant therapy and showed
pCR. A higher pCR to neoadjuvant therapy was also found
in Group 1 in comparison to the other Groups (Groups 2–5),
which had no pCR (p = 0.11). Approximately 67% of cases
were pN0 and the majority of the group cases were ER- and
PR-positive, 72 and 56%, respectively. Most cases had
HER2 IHC 2+ or 3+ staining (169 cases [97%], 2+: 146
cases [84%], and 3+: 23 cases [13%]).
With regards to outcomes, Group 1 patients had a better
OS and DFS, suggesting that the higher HER2

ampliﬁcation, the better the response to HER2-targeted
medications. Due to the lack of enough negative control
cases (i.e., Group 5 cases), Group 1 was used as the baseline
comparison group for both OS and DFS.

Group 1 subcategories
Since Group 1 (HER2/CEP17 ratio ≥ 2 + HER2 signal ≥ 4
per cell) is a broad group and the dominant category in
terms of number of patients in our cohort (176 [78%] out of
226), and because it shows signiﬁcant heterogeneity in
response to HER2 agents, we proposed three subcategories
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Fig. 3 Kaplan–Meier plot (left) and Cox model (right) for overall survival by 2018 ASCO–CAP HER2 FISH Groups. CI conﬁdence interval,
FISH ﬂuorescence in situ hybridization, HR hazard ratio. Bolded values indicate statistically signiﬁcant results.

Fig. 4 Kaplan–Meier plot (left) and Cox model (right) for disease-free survival by 2018 ASCO–CAP HER2 FISH Groups. CI conﬁdence
interval, FISH ﬂuorescence in situ hybridization, HR hazard ratio. Bolded values indicate statistically signiﬁcant results.

under “Group 1/classical ampliﬁcation” category to look for
any potential differences in outcomes in patients who
received HER2-targeted agents. These three subcategories
included low ampliﬁed (HER2/CEP17 ratio ≥ 2.0–2.99,
mean HER2/cell 4.0–5.9), ampliﬁed (HER2/CEP17 ratio

≥ 2.0–2.99, mean HER2/cell ≥ 6), and excessive ampliﬁcation (HER2/CEP17 ratio ≥ 3.0 and HER2/cell ≥ 4.0). The
cutoffs for subcategories are based on the expert opinion of
one experienced molecular and breast pathologist (DC) and
published literature [5, 12].
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Table 2 Cox regression for
overall and disease-free survival
using standard prognostic
variables.

Prognostic variable

Hazard ratio

Lower .95

Upper .95

p value

Tumor type

3.0388

1.7407

5.305

9.25 × 10−5

Nottingham grade

0.9422

0.6846

1.297

0.7148

Pathologic tumor stage (pT)

1.1076

0.8480

1.447

0.4532

Pathologic lymph node stage (pN)

0.8504

0.6531

1.107

0.2290

ER

1.7590

0.9906

3.124

0.0539

Overall survival

PR

0.7111

0.4264

1.186

0.1915

HER2 IHC

0.7177

0.4879

1.056

0.0921

Tumor type

2.6552

1.4963

4.712

0.0008

Nottingham grade

0.8722

0.6361

1.196

0.3960

Disease-free survival

Pathologic tumor stage (pT)

1.2423

0.9337

1.653

0.1364

Pathologic lymph node stage (pN)

0.8707

0.6706

1.131

0.2987

ER

1.6053

0.9130

2.823

0.1002

PR

0.6708

0.4031

1.116

0.1244

HER2 IHC

0.7595

0.5199

1.109

0.1547

ER estrogen receptor, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, PR
progesterone receptor.
Table 3 Cox regression for overall and disease-free survival using
only tumor type and ASCO–CAP 2018 ISH Groups.
Prognostic variable

Hazard ratio Lower .95 Upper .95 p value

Overall survival
Tumor type

2.180

1.345

3.532

0.0015

ASCO–CAP
ISH Groups

1.296

1.111

1.513

0.0010

Tumor type

1.837

1.111

3.040

0.0178

ASCO–CAP
ISH Groups

1.325

1.136

1.546

0.0003

Disease-free survival

ASCO–CAP American Society of Clinical Oncology–College of
American Pathologist, ISH in situ hybridization.

Figure 5 and Table 4 show case distribution and the
histopathologic features of each entity. They demonstrate
strikingly similar frequencies of almost all histopathologic
features among the subgroups. Of note, no signiﬁcant
relationship between these subcategories and histopathologic features is noted except for HER2 IHC. The excessive
ampliﬁcation subcategory was signiﬁcantly associated with
HER2 IHC 3+ cases (p < 0.01).
Patients in the low-ampliﬁed subcategory received trastuzumab (Herceptin) alone in 30 (54%) patients while 26
(46%) patients received trastuzumab (Herceptin) with pertuzumab (Perjeta). Almost half of the ampliﬁed subcategory
patients (20 patients) received trastuzumab (Herceptin)
alone and the other half (22 patients) received trastuzumab
(Herceptin) with pertuzumab (Perjeta). Excessive ampliﬁcation patients were mainly treated with trastuzumab
(Herceptin) alone (64 [85%] patients) and only 11 (15%)

patients received trastuzumab (Herceptin) in combination
with other drug [9 patients with pertuzumab (Perjeta) and 2
patients with lapatinib (Tykerb/Tyverb)]. Excessive ampliﬁcation patients who received trastuzumab (Herceptin)
alone had the longest median survival (483.4 weeks for OS
and 481.6 weeks for DFS) as well as lowest HRs (Fig. 6)
(OS HR = 0.60, 95% CI 0.37–0.96; p = 0.035 and DFS HR
= 0.57, 95% CI 0.36–0.92; p = 0.022) even after controlling for tumor type in Cox regression model for OS (HR =
0.53, 95% CI 0.32–0.87; p = 0.012).
Complete response to neoadjuvant therapy was not statically signiﬁcant between the excessive ampliﬁcation subcategory and the other two categories (p = 0.29), despite
23% (6 out of 26 cases) rate of pCR after neoadjuvant
therapy in excessive ampliﬁcation group as opposed to 11%
(3 out 28 cases) in the other two subcategories.
The proposed subcategories were signiﬁcantly associated
with OS (p < 0.01; Fig. 7) and DFS (p < 0.01) using log rank
test, excessive HER2 ampliﬁcation was associated with
longest median survival (475 weeks for OS and 474 weeks
for DFS), possibly reﬂecting a better response to HER2targeted therapy. Group 1 subcategories were not statistically
signiﬁcantly associated with metastasis (p = 0.15), recurrence (p = 0.07), or second breast primary (p = 0.81).
The Cox regression models showed better survival outcomes for the excessive ampliﬁcation subgroup than the
low ampliﬁed subgroup, with OS (HR = 0.63, 95% CI
0.42–0.93; Fig. 7) and DFS (HR = 0.55, 95% CI
0.37–0.83). Similar ﬁndings were seen after including the
rest of the ASCO–CAP HER2 ISH groups in the regression
model (Fig. 8).
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Fig. 5 Case distribution of Group 1 subcategories along with their ISH deﬁnitions. CEP chromosome enumeration probe, HER2 human
epidermal growth factor receptor 2, ISH in situ hybridization.

Group 2/“nonclassical” monosomy (HER2/CEP17
ratio ≥ 2 + HER2 signal < 4 per cell)

Fig. 4), possibly suggesting inferior response to HER2targeted therapy.

Our cohort had 17 (7.5%) cases that showed HER2/CEP17
ratio ≥ 2 + HER2 signal < 4 per cell. The median age was
64 years (range 43–89), median HER2 FISH ratio was 2.15
(range 2–3.28), and median HER2 signal/cell was 3.50
(range 2.08–3.98). Fifteen (88%) cases had 2+ staining for
HER2 IHC and 2 (22%) cases had 0–1+ staining. Since
there were no 3+ cases, all cases in this cohort are categorized as negative for HER2 FISH according to the latest
guidelines (2+ cases require a count from an additional
observer and if the count remains the same then negative
result is rendered).
When compared to Group 1 category, Group 2 showed
inferior survival outcomes for both OS (HR = 3.06, 95% CI
1.61–5.8; Fig. 3) and DFS (HR = 3.70, 95% CI 1.98–6.9;

Group 3/“nonclassical” co-ampliﬁed/polysomy
(HER2/CEP17 ratio < 2 + HER2 signal ≥ 6 per cell)
Only 11 out of 226 (5%) cases were recorded in this group.
The median age was 66 years (range 43–83), median HER2
FISH ratio was 1.56 (range 1.38–1.92), and median
HER2 signal/cell was 6.37 (range 6.20–8.22). The tumors
were HER2 IHC 2+ (10 cases) and HER2 IHC 3+ (1 case).
All of our cases in this cohort are categorized as ISHpositive according to the latest guidelines (2+ cases require
a count from an additional observer and if the count remains
the same then positive result is rendered).
When compared to Group 1 category, Group 3 showed
inferior clinical outcomes for both OS (HR = 2.42, 95% CI
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Table 4 Histopathologic characteristics of cases within Group
1 subcategories.
Low
ampliﬁed

Ampliﬁed

Excessive
ampliﬁcation

p value

69 (92%)

1.00

Tumor type
Ductal NST

51 (89%)

Lobular

1 (2%)

Special type

2 (4%)

Mixed

1 (2%)

39 (89%)
0
3 (7%)
0

4 (5%)
1 (1%)
0

Nottingham grade
Grade 1

1 (2%)

2 (5%)

3 (4%)

Grade 2

19 (33%)

18 (41%)

28 (37%)

Grade 3

34 (60%)

19 (43%)

40 (53%)

0.67

Pathologic tumor stage (pT)
ypT0 and ypTis

2 (4%)

2 (5%)

8 (11%)

pT1

25 (44%)

19 (43%)

38 (52%)

pT2

16 (28%)

10 (23%)

16 (21%)

pT3

5 (9%)

0

pT4

3 (5%)

0

0.08

0
1 (1%)

(range 1.18–1.97), and median HER2 signal/cell was 5.10
(range 4.28–5.98). According to the 2018 ASCO–CAP
guidelines, cases under this category with HER2 2+ are
ISH-negative, if the count remains the same from an additional observer, while HER2 3+ are classiﬁed ISH-positive.
From our cohort, 18 cases had 2+ staining for HER2 IHC,
i.e., negative, while only 1 case had 3+ staining for HER
IHC and was classiﬁed HER2-positive.
The case that had 3+ IHC was a poorly differentiated
invasive ductal carcinoma in a 69-year-old patient, had
lymphovascular invasion with pT2 pN2a disease, ER was
100% and PR was 65%. The patient received adjuvant
chemo- and radiotherapy along with hormonal treatment
and is still alive with no evidence of metastasis, second
primary, or recurrence.
When compared to Group 1 category, Group 4 showed
inferior clinical outcomes for both OS (HR = 2.15, 95% CI
1.28–3.6; Fig. 3) and DFS (HR = 2.08, 95% CI 1.22–3.5;
Fig. 4), possibly suggesting inferior response to HER2targeted therapy.

Pathologic lymph node stage (pN)
pN0

29 (51%)

pNmic

0

20 (45%)
0

44 (59%)

pN1

8 (14%)

8 (18%)

9 (12%)

pN2

6 (11%)

4 (9%)

4 (5%)

pN3

2 (4%)

0

0.66

2 (3%)

2 (3%)

Neoadjuvant Therapy
Pathological
complete
response (pCR)

1/18 (6%) 2/10 (20%) 6/26 (23%)

0.29

Estrogen receptor (ER)
ER+

39 (68%)

33 (75%)

52 (69%)

ER−

17 (30%)

9 (20%)

22 (29%)

0.59

Progesterone receptor (PR)
PR+

28 (49%)

29 (66%)

40 (53%)

PR−

28 (49%)

13 (30%)

34 (45%)

1 (2%)

3 (7%)

1 (1%)

2+

54 (95%)

41 (93%)

3+

1 (2%)

0.15

HER2 IHC
0–1+

0

<0.01

Group 5/classical non-ampliﬁed (HER2/CEP17 ratio
<2 + HER2 signal <4 per cell)
Three patients (1%) belonged to this group, all of whom
received HER2-targted therapy based on equivocal
results from 2007 guidelines as these cases were diagnosed in 2007, 2008, and 2010. The median age was 59
years (range 42–86), median HER2 FISH ratio was 1.84
(range 1.82–1.96), and median HER2 signal/cell was
3.82 (range 3.40–3.90). HER IHC 2+ was recorded for
all cases.
Due to low case volume in this cohort, survival outcomes
cannot be ascertained. However, out of three patients only
two are alive while the third patient passed away due to
breast cancer and metastatic disease. One of the living
patients developed metastasis, suggesting poor response to
HER2-targeted therapy.

51 (68%)
22 (29%)

Ductal NST ductal carcinoma of no special type, HER2 human
epidermal growth factor receptor 2, IHC immunohistochemistry.

1.18–5.0; Fig. 3) and DFS (HR = 3.95, 95% CI 1.97–7.9;
Fig. 4), possibly suggesting inferior response to HER2targeted therapy.

Group 4/“nonclassical” equivocal (HER2/CEP17 ratio
< 2 + HER2 signal ≥ 4–< 6 per cell)
There were 19 (8.5%) cases recorded. The median age was
66 years (range 42–82), median HER2 FISH ratio was 1.64

HER2 signals per cell
Adopted from published literature, cases were also grouped
into three categories based on average HER2 copy-number
per cell alone, using a cutoff system of <6 copies (n = 99
cases), 6–10 copies (n = 76 cases), and >10 copies (n = 51
cases) to investigate whether this classiﬁcation predicts
outcome and is the increasing success of anti-HER2 therapy
in this setting driven more by the “numerator” than the ratio.
Cases with >10 copies of HER2 per cell showed superior
survival outcomes for both OS (HR = 0.45, 95% CI
0.30–0.66; Fig. 9) and DFS (HR = 0.42, 95% CI 0.28–0.63;
Fig. 9) in comparison to cases with <6 copies of HER2signals per cell.
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Fig. 6 Kaplan–Meier plot of overall survival (left) and Cox models
for both overall survival and disease-free survival (right) by
Group 1 subcategories and HER2-targeted agents received. CI

conﬁdence interval, HR hazard ratio. Bolded values indicate statistically signiﬁcant results.

Fig. 7 Kaplan–Meier plot of overall survival (left) and Cox models for both overall survival (top right) and disease-free survival (bottom
right) by Group 1 subcategories. CI conﬁdence interval, HR hazard ratio. Bolded values indicate statistically signiﬁcant results.

Discussion
We retrospectively applied different classiﬁcation systems
of HER2 FISH based on the latest ASCO–CAP guidelines
to a unique cohort of patients that was exclusively treated

with HER2-targeted agents in a non-trial setting in our
institution from 2006 to 2017 and studied their prognostic
signiﬁcance. Limited data exists in the literature assessing
the association of level of HER2 ampliﬁcation and response
to HER2-targeted agents. There are some reports showing a
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Fig. 8 Kaplan–Meier plot of overall survival (left) and Cox models
for both overall survival and disease-free survival (right) by
Group 1 subcategories and 2018 ASCO–CAP HER2 ISH Groups

2–5. CI conﬁdence interval, HR hazard ratio. Bolded values indicate
statistically signiﬁcant results.

Fig. 9 Kaplan–Meier plot of overall survival (left) and Cox models for both overall survival (top right) and disease-free survival (bottom
right) by average HER2 signals per cell. CI conﬁdence interval, HR hazard ratio. Bolded values indicate statistically signiﬁcant results.

positive relation between level of HER2 ampliﬁcation by
ISH and rate of pathological complete response to
trastuzumab-based neoadjuvant treatment [13, 14]. In our
cohort, 17% of cases in Group 1 that received neoadjuvant

therapy showed pCR. This was not statistically signiﬁcant
when compared to other groups. Twenty-three percent of
patients in the excessive ampliﬁcation subcategory showed
pCR to neoadjuvant therapy, but again this was not
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statically signiﬁcant when compared to the other two subcategories (11% in the other two subcategories of Group 1).
About 95% of all performed HER2 FISH results belonged to the classical category either ampliﬁed (Group 1) or
non-ampliﬁed (Group 5) [15]. The threshold of both groups
remained unchanged by the new guidelines and it is welldocumented that cases with HER2 overexpression demonstrate clinical beneﬁt when HER2-targeted agents like
trastuzumab (Herceptin) [16, 17], lapatinib (Tykerb/Tyverb)
[18], pertuzumab (Perjeta) [19], and ado-trastuzumab
emtansine/T-DM1 (Kadcyla) [20, 21] are used.
The vast majority of our cohort received trastuzumab
(Herceptin) alone (145 (64%) patients) while the remaining
patients received trastuzumab (Herceptin) in combination
with pertuzumab (Perjeta) or lapatinib (Tykerb/Tyverb) in
74 (33%) patients. The use of trastuzumab (Herceptin)
alone was signiﬁcantly associated with longer median OS
and DFS. Similarly, excessive ampliﬁcation subcategory
patients who received trastuzumab (Herceptin) alone had
the longest median survival as well as lowest HRs for OS
and DFS. We acknowledge that our results might have been
confounded by the fact that this is a retrospective review
and the fact that we used pertuzumab (Perjeta) and lapatinib
(Tykerb/Tyverb) in higher risk patients than those who
received trastuzumab (Herceptin) alone.
Data on the histopathologic features and prognosis are
limited in the literature on the nonclassical category
(Groups 2–4) due to their rare inclusion in clinical trials and
partly due to their low incidence (5% of cases) [5, 8]. In our
study and from our unique cohort, the incidence of nonclassical cases was 21%. Table 1 demonstrates the histopathologic characteristics of each nonclassical group.
Group 1, deﬁned as ISH-positive and HER2 ampliﬁed,
compromised the vast majority of cases (176 [78%] out
226) and was superior to the other groups in having fewer
deaths and better survival outcomes. This ﬁnding suggests
that the higher HER2 expression the better response to
HER2-targeted medications. We also have demonstrated
that some heterogeneity exists in relation to response to
HER2 treatments because our three proposed subcategories
(low-ampliﬁed, ampliﬁed, and excessive ampliﬁcation)
showed signiﬁcant association with OS (p < 0.01; Fig. 7)
and DFS (p < 0.01). In addition, the highest HER2/CEP17
ratio (excessive ampliﬁcation subgroup) was associated
with the longest median survival for both OS and DFS
(Fig. 8) when compared to the rest of the ASCO–CAP
HER2 ISH Groups, supporting our theory that these cases
would have a better response to HER2-targeted therapy.
This novel ﬁnding warrants additional investigation as our
ﬁndings suggest different response to HER2 therapy within
the same category. Although one would argue that these
cases represent HER2 IHC 3+ cases, and thus, scant ISH
data in the literature since most laboratories do not perform

ISH when the HER2 IHC is 3+. From our cohort, excessive
ampliﬁcation subcategory was indeed enriched with HER 3
+ cases (22 [30%] cases, p < 0.01), but the vast majority of
cases (51 [~70%] cases) were HER IHC 2+. The current
HER2 ISH interpretation does not stratify classic ampliﬁcation as high or low in Group 1 cases. We recommend
reporting these subcategories or include a comment that
speciﬁes high or low ampliﬁcation, which is similar in
concept to the “low positive” category, which was recently
introduced in the ASCO–CAP update on ER testing when
the staining is between 1 and 10% [22]. However, larger
and prospective longitudinal studies are needed to validate
our ﬁndings.
Group 2 is seen in cases with loss of a chromosome (true
monosomy) or part of the chromosome (CEP17) [5]. When
such a case is encountered in dual-probe ISH, additional
work is required to render a ﬁnal result. In our study, only
17 (7.5%) cases were recorded in this group. It also contained the highest number of 0–1+ HER2 IHC cases in the
nonclassical category, 12%, with no HER 3+ cases. After
applying the new ASCO–CAP guidelines, all of our Group
2 cases would have been classiﬁed as ISH-negative. Despite
the low number of cases, our cases showed inferior survival
outcomes compared to Group 1, possibly suggesting inferior response to HER2-targeted therapy, a ﬁnding that supports the current reporting scheme and the literature as
described by Press et al. [15] and Risio et al. [23].
Group 3 cases are seen when the ratio is negative, but
HER2 signals are more than 6 per cell, and are due to gain
of the pericentromeric region of chromosome 17 rather than
the rare true polysomy, i.e., gain of an entire chromosome
[24–26]. In our study, Group 3 contained the lowest number
of patients in the nonclassical category (11 patients [5% of
cohort]) with 91% of the cases being HER IHC 2+. Group
3 has limited data on response to HER2-targeted therapies
with one study showing that patients in this group who did
not receive HER2-targeted therapy had a worse outcome
(OS and DFS) than Group 5 or ISH non-ampliﬁed cases
[15]. In addition, it is well-described in the literature that
Group 3 comprises two heterogeneous groups: one ampliﬁed and the other is not ampliﬁed. Press et al. [27] found
that the ampliﬁed group had an average of 12.3
HER2 signals per cell and was predominately HER2 IHC 2
+ and 3+, while the non-ampliﬁed group had an average of
6.8 HER2 signals per cell and was predominately HER2
IHC 0–1+. From our study, the average HER2 signals per
cell in this category was 6.79 and all of our cases were
HER2 IHC 2+ (ten cases) and 3+ (one case), thus considered ISH-positive based on the current guidelines. In
terms of survival, Group 3 cohort showed inferior survival
outcomes in contrast to Group 1, suggesting that these cases
belong to the non-ampliﬁed group despite having HER2
IHC 2+ and 3+ and contradict the designation of ISH-
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positive according to the latest reporting scheme. However,
due the low number of cases in this group, it is hard to draw
a deﬁnite conclusion, and larger prospective studies are
needed.
Group 4, formerly referred to as ISH equivocal, has
frequent cells with slight increase in HER2 signals (≥4–<6)
per cell with simultaneous mild increase in mean
CEP17 signals per cell or non-clustered scattered distribution of cells with ≥6 signals of HER2 per cell [5]. In our
study, 19 (8.5%) patients were recorded with 5% (1 case)
being HER2 IHC 3+, 95% (18 cases) being HER2 IHC 2+
and no HER2 IHC 0–1+ cases. In order to adjudicate these
cases, ASCO–CAP guidelines require incorporating IHC
results and recommend against the use of alternative chromosome 17 probes [8]. From our cohort, the one HER2 3+
case is the only case classiﬁed as ampliﬁed while the rest
were non-ampliﬁed. In one study, Group 4 cases were
included in a clinical trial that received chemotherapy but
not HER2-targeted agents, and the outcomes were similar to
the negative control (non-ampliﬁed cases/Group 5) [15].
Given that 18 out of 19 cases are ISH-negative, these cases,
despite the low number, showed inferior clinical outcomes
than Group 1 and possibly suggests an inferior response to
HER2-targeted therapy. This ﬁnding supports the current
reporting scheme to consider these cases (especially the
HER2 2+) as ISH-negative. However, larger studies are
needed to validate this ﬁnding.
Group 5, classical non-ampliﬁed, had three cases (1% of
the entire cohort). These were old equivocal cases based on
older guidelines in which the treating oncologist decided to
treat with HER2-targeted agents. We acknowledged that the
small number of cases was insufﬁcient for deﬁnitive evaluation for outcome or response to HER2-targeted therapy.
In contrary to a systematic review and meta-analysis by
Xu et al. [12], which showed that different HER2 gene
copy-number level had no prognostic value on survival for
those who received trastuzumab-based adjuvant treatment,
categorizing the cases solely based on the average number
of HER2 signals per cell (<6 copies, 6–10 copies, and >10
copies) enabled us to predict clinical endpoints in our
cohort. Cases with >10 copies of HER2 showed longer
median OS and DFS when compared to the other categories, suggesting superior response to HER2-targeted
agents and suggesting that the increasing success to
HER2-targeted agents could also be driven by the absolute
number of HER2 signals rather than the ratio. Larger and
prospective longitudinal studies are needed for validation.
To summarize the impact of implementing the new 2018
ASCO–CAP guidelines in our cohort, 36 (15.9%) cases
changed their category compared to the 2013 guidelines, a
rate which is slightly higher than what Zare et al. reported
(10.7%) [28]. The 2018 ASCO–CAP reclassiﬁcation of

cases was signiﬁcantly associated with OS (p = 0.003) and
DFS (p = 0.001) using the log rank test.
Low number of cases in some of the groups is one of the
limitations of our study. Despite that, our HER2-treated
cohort provides a solid start for future studies. Another
drawback of this cohort pertains to the inherent limitation of
FISH slides that cannot be rescored using current
ASCO–CAP guidelines for an additional blinded observer
scoring, a step that is now required for HER2 2+ in Groups
2–4 cases. In addition, HER2 IHC interpretation was
updated in the 2018 ASCO–CAP update [8], it resulted in
an increase in HER2 0–1+ cases and a decrease in 2+
cases, all of the HER2 IHC results provided in our study
were recorded based on prior guidelines. Finally, our study
lacked data on HER2 heterogeneity. The literature data on
the latter are limited with conﬂicting deﬁnitions and a
reported rate of <1% of total cases as described in a study
by Ballard et al. [5].
In conclusion, our retrospective, single-institution,
HER2-treated cohort study supports the new ASCO–CAP
2018 guidelines binary reporting scheme and we recommend reporting each speciﬁc group due to the heterogeneity
in response to HER2-targeted agents. We also recommend
reporting ASCO–CAP Group 1 ISH subcategories for every
patient since the current HER2 ISH interpretation does not
stratify classic ampliﬁcation as high or low and our data
showed that excessive ampliﬁcation is associated with the
longest median survival for both OS and DFS, subject to
larger and prospective longitudinal studies to validate our
ﬁndings.
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